

From: Kiran Mazumdar/Corporate/BIOCON <kiran.mazumdar@biocon.com>

To: Haley, NikkiNikkiHaley@gov.sc.gov

CC: Veldran, KatherineKatherineVeldran@gov.sc.gov
gpatrick@scommerce.comgpatrick@scommerce.com
latha.sharma@biocon.comlatha.sharma@biocon.com

Date: 11/27/2014 1:29:15 AM

Subject: MEETING WITH GOVERNOR HALEY / PERSPECTIVE ON STATE BIOSIMILAR
LEGISLATION

Attachments: US -India Pharma bilateral co-opoerataion John Kerry.pdf
e-LAJ Jaipur.pptx

Dear Governor Haley,

It was such a pleasure to meet with you and your husband in Chennai last week. I truly enjoyed our wide ranging discussions which left me most impressed with your dynamic thought leadership that has propelled South Carolina into global manufacturing leadership especially in the automotive sector. I do believe that your India visit was perfectly timed. Prime Minister Modi is also a "man in a hurry", who is committed to radical reforms focused on job-driven growth and regulatory reforms that will focus on ease of doing business in India.

As discussed, I am keen to see our two countries as committed strategic partners in delivering Global Healthcare. I am attaching a letter I wrote to Secretary Kerry on this subject and I would particularly like to draw your attention to two key aspects of Healthcare -- Access and Affordability -- which, I am sure you will agree, are aspects that the US is also keenly focused on. India has played an important role in driving down costs of US Healthcare through Generic Drugs.

The next phase of driving down drug-related costs is now about Biogenerics or Biosimilars. As explained, my company Biocon has partnered with US Generics Company Mylan to develop a pipeline of Biogenerics for Cancer and Diabetes, which have the potential of significantly reducing the high costs presently incurred on Biologic drugs. As was seen during the early years of the Hatch-Waxman era of generic drugs, there is a concerted effort by 'big Pharma' to perpetuate their market monopolies for biological drugs. This is often done through advocacy of state legislation that, in the guise of promoting access and affordability, actually seeks to undermine the determination by the FDA that a biological product is substitutable or interchangeable through onerous reporting, labelling or documentation requirements. It would be welcome if South Carolina, under your leadership, resists such legislative or administrative attempts to limit patient access to these more affordable biological drugs.

On the e-Health front, I am attaching a presentation of the pilot that we are running on the concept of e-Primary Health Centres, Tele medicine and e-health Coupons.

I look forward to our paths crossing again before too long.

John joins me in sending you both our warmest wishes,

Kiran

Kiran Mazumdar-Shaw

CHAIRMAN AND MANAGING DIRECTOR

Biocon Limited | 20th KM, Hosur Road, Electronic City, Bangalore - 560100, India

E: kiran.mazumdar@biocon.com | T: +91 80 2808 2808

W: www.biocon.com

Confidential and Privileged :

This message is for the designated recipient only and may contain privileged, proprietary, or otherwise private information. If you have received it in error, please notify the sender immediately and delete the original. Any other use of the e-mail by you is prohibited. Opinions, conclusions and other information in this transmission that does not relate to the official business of this Company shall be understood as personal and not endorsed by the company. Any statements made herein that are tantamount to contractual obligations, promises, claims or commitments shall not be binding on the Company unless followed by written confirmation by an authorized signatory of the Company

Please consider the environment before printing this email